Fundamental and Clinical Evaluation of a PIVKA-II Kit, “PIVKA-II IRMA 'Daiichi, <SUP>®</SUP>”

DOI Web Site Web Site 10 References

Bibliographic Information

Other Title
  • PIVKA-II IRMA「第一」<SUP></SUP>の基礎および臨床的検討
  • PIVKA-2 IRMA「第一」の基礎および臨床的検討
  • PIVKA-2 IRMA ダイイチ ノ キソ オヨビ リンショウテキ ケントウ
  • Fundamental and Clinical Evaluation of a PIVKA-II Kit, &ldquo;PIVKA-II IRMA 'Daiichi, <SUP>&reg;</SUP>&rdquo;

Search this article

Abstract

We evaluated the characteristics and clinical efficacy of the“PIVKA-II IRMA‘Daiichi, ®”kit for estimating the serum PIVKA-II levels in hepatocellular carcinoma patients. Intraassay and interassay variances were within 10%. Recovery and dilution tests also gave satisfactory results. There was no significant effect of reaction time on PIVKA-II levels. However, PIVKA-II levels were significantly lower in heparinized plasma than those in serum and EDTA plasma. The cut-off level was determined as 40mAU/mL, mean +3SD of PIVKA-11 level in 84 normal control subjects. The sensitivity and specificity of“PIVKA-IIIRMA lsquo;Daiichi, ®”kit for hepatocellular carcinoma patients was 81; 6% and 82.4%, respectively. A significant correlation was observed between PIVKA-II levels measured by“PIVKA-II IRMA‘Daiichi, ®”kit and “EitestR Mono P II”EIA kit (r=979) . In conclusion, “PIV-KA-II IRMA‘Daiichi, ® kit is considered to be accurate and useful for measuring PIVKA-II levels in hepatocellular carcinoma patients.

Journal

  • RADIOISOTOPES

    RADIOISOTOPES 48 (3), 188-194, 1999

    Japan Radioisotope Association

References(10)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top